Type 2 diabetes is associated with a high prevalence of comorbidities resulting from hypertension, dyslipidemia, and hyperglycemia. Inadequate management of these risk factors will eventually result in detrimental health consequences. Thus, the effect of a drug on factors such as weight, cardiovascular (CV) risk factors, and adherence is important to consider. A review was undertaken of the recent medical literature describing the extraglycemic characteristics of the two classes of incretin-based therapiesglucagon-like peptide-1 receptor agonists (GLP-1RA) and dipeptidyl peptidase-4 (DPP-4) inhibitors. PubMed searches were performed to identify published data on incretin therapies that describe their effects on CV risk factors, CV events, and factors related to medication adherence. The maintenance or loss of weight associated with the use of GLP-1RAs and DPP-4 inhibitors is well described in the medical literature. These agents also appear to be associated with a modest decrease in blood pressure and a reduced risk of CV events. In addition, several characteristics of incretin therapies may improve rates of medication adherence, such as generally favorable tolerability profiles (particularly with DPP-4 inhibitors), the availability of formulations that simplify treatment regimens, and a low risk for hypoglycemia. The literature on incretin therapies describes a number of clinical characteristics that are relevant to the management of extraglycemic risk factors. As part of a holistic treatment strategy, these properties constitute important considerations for tailoring therapy to individual patients with type 2 diabetes.
INTRODUCTION
The high prevalence of comorbidities associated with type 2 diabetes exerts a significant socioeconomic burden on the US healthcare system. For example, diabetes is the leading cause of end-stage renal disease [1] . One retrospective study of [91,000 patient records reported an incidence of chronic kidney disease of *15% in individuals with both type 2 diabetes and hypertension, compared with only 1.1% and 1.5% in patients with diabetes or hypertension alone, respectively [2] . Diabetes is also a leading cause of blindness in US adults. A recent pooled analysis of data from more than 23,000 patients reported that the prevalence of diabetic retinopathy may be as high as 35% [3] .
Approximately 7 million patients with diabetes had retinal disease in 2005, and it has been predicted that this number will increase to 19 million by the year 2050 [4] . Against this background, physicians must take into consideration a complex set of variables when discussing treatment options with patients who have type 2 diabetes. In the current era of medical research, the clinical and pharmacologic characteristics of antidiabetic agents are being evaluated in greater depth than just a few decades ago and, as a result, our understanding of these medicines now extends far beyond their role in glycemic control. While the effects of a drug on factors such as weight, cardiovascular (CV) risk, and medication adherence were once considered secondary to the efficacy of the drug for reducing blood glucose, now many patients and physicians consider such factors when 
MATERIALS AND METHODS
PubMed searches were conducted for literature describing the extraglycemic effects of incretinbased therapies. The following terms were used to search among English language publication titles in the PubMed database: (incretin [ 18 December 2012, with additional searches on specific topics as required to update the review. No date restrictions were specified. PubMed abstracts were qualitatively reviewed and individually selected based on their relevance to the review topic. Articles that were considered relevant based on an assessment of an abstract were obtained and further evaluated, with attention to references cited for further resources.
CARDIOVASCULAR RISK

Weight
In obese individuals, the risk of developing type 2 diabetes is elevated *sevenfold relative to those with normal body weight [5] . The presence of diabetes and obesity elevates the risk (individually and in combination) of numerous complications and comorbidities, including CV disease, hypertension, and stroke. Cardiovascular disease alone is responsible for *65% of deaths in patients with type 2 diabetes [6] . Therefore, given that most individuals with type 2 diabetes are obese, weight reduction is a key strategy to reduce morbidity and mortality.
The Action for Health in Diabetes (Look AHEAD) study was designed to provide a quantitative assessment of the association between modest weight reduction in overweight/obese patients with type 2 diabetes and the incidence of severe CV events (heart disease, stroke, and CV-related deaths). The study began in 2001 and was scheduled to complete in 2014. In the first year of Look AHEAD, patients participating in intensive lifestyle intervention (N = 2,503) lost *7-9% of body weight [7] . This was associated with a 25-33 mg/dL decrease in serum triglycerides (TG) and a 5-8 mmHg reduction in systolic blood pressure (SBP). As a reference for the clinical relevance of this magnitude of blood pressure (BP) reduction, in the United Kingdom Prospective Diabetes Study (UKPDS), each 10 mmHg reduction in SBP was associated with an 11% reduced risk of myocardial infarction, a 12% reduction in the risk of any diabetes complications, and a 13% reduction in the risk for microvascular disease [8] . In addition, the 7-9% reduction in body weight in Look AHEAD was also associated with a 2-5 mg/dL increase in high-density lipoprotein cholesterol (HDL-C), and a 4-7 mg/dL decrease in low-density lipoprotein cholesterol (LDL-C) [7] . For reference, note that a 23-mg/dL decrease in total cholesterol (TC) can reduce the risk of coronary heart disease by up to 30% [9] [10] [11] [12] .
Thus, significant improvements in CV risk factors may be achieved through modest reductions in body weight.
The Look AHEAD study was terminated early based on the results of an interim analysis [13] .
It was determined that the rate of severe CV events in the treatment group (intensive lifestyle intervention) was not significantly different from that in the control group (diabetes support and education) and that given the 11-year study duration, this was not likely to change. Although the intensive lifestyle intervention has been discontinued, patients will continue with follow-up as a means of assessing any potential long-term effects of the intervention, for example, through metabolic memory (the 'legacy effect'). The results of the long-term follow-up of patients participating in Look AHEAD will help to more specifically inform treatment decisions related to lifestyle intervention.
Clinically significant weight loss is potentially within the pharmacologic effect of GLP-1RAs (Fig. 1) . In clinical trials, weight loss with exenatide [14] [15] [16] [17] and liraglutide have generally ranged from 2% to 4% of initial body mass ( with once-weekly exenatide; in a trial that compared once-weekly exenatide with the original twice-daily formulation, the mean SBP reductions from baseline were -2.9 and -1.2 mmHg, respectively [28] . Multiple metaanalyses have recently been conducted in review of the CV effects of DPP-4 inhibitors [60] [61] [62] [63] [64] . In these reports, the mean change in SBP was generally in the range of 1-4 mmHg for linagliptin [61] and saxagliptin [60] .
The mechanism by which these agents reduce BP is not yet clear. One retrospective analysis combined data from three exenatide trials (N = 686 patients) to assess the relationship among SBP reduction, weight loss, and glycemic control [65] . This study utilized a method of internal referencing, whereby patients were categorized into groups according to those achieving HbA1c reduction and weight loss greater or less than the weighted mean. Patients above the weighted mean for HbA1c reduction, weight loss, or both had, respectively, 30%, 61%, and 88% higher chances of lowering SBP \130 mmHg (compared with those below the mean). This suggests that blood glucose-lowering and weight loss may contribute independently to BP-lowering, with synergism when both factors are combined; however, at this time, such interpretation is still preliminary and requires further study as other unknown factors may also contribute. One recent study in 61 patients receiving exenatide for a mean of 1.4 years evaluated the correlation between weight loss and SBP reduction and concluded that the BP reduction was not significantly associated with weight loss [66] .
Lipids
One study reported a significant improvement in fasting TC and HDL-C with exenatide therapy [67] , which is consistent with an earlier report that demonstrated significant improvements in fasting TG and TC, HDL-C, and LDL-C with this agent [34] . Postprandial measurements have also shown lipid improvement with exenatide; Meier et al. [68] reported a non-significant increase in postprandial TG (-0.023 mmol/L) versus [71] . Data show that the primary non-inferiority safety endpoint has been met; saxagliptin does not increase CV events compared with placebo when added to the patient's standard-of-care regimen (with or without other antidiabetic medications). Since results did not show a decrease in the risk of overall CV events with saxagliptin versus comparators, the trial did not meet the primary efficacy objective of superiority [72] .
CARDIOVASCULAR EVENTS
When fully available, these studies will provide long-term data on the CV effects of DPP-4 inhibitors in patients with type 2 diabetes. These data will address an important need in the medical literature, particularly considering that some data have suggested an exacerbation of CV risk with the more commonly prescribed SUs, especially when used in combination with metformin. For example, in the UKPDS study, the early addition of metformin to an SU was associated with a 96% increase in diabetes-related deaths compared with continued SU use [73] . Later studies provided additional data that described this association. One study reported an adjusted 43% increase in total mortality and an adjusted 70% increase in CV mortality in patients taking an SU versus metformin [74] . A retrospective review of the UK General Practice Research Database showed that the combination of metformin and SU increased mortality by 24-61% (P = 0.001) and heart failure by 18-30% relative to metformin monotherapy [75] . Meta-analyses on this subject have also described adverse outcomes associated with SUmetformin combination therapy [76, 77] .
Considering the high prevalence of CV mortality in patients with diabetes, the importance of medications with favorable CV safety profiles cannot be understated. At the very least, medications for the treatment of diabetes should be neutral if not actively preventive with regard to CV risk factors and outcomes. The current literature on incretinbased therapies is promising in this respect and, in the coming years, we can expect the CV literature to provide a more detailed view of these and other antidiabetic therapies.
SUSTAINABILITY OF THE PRESCRIBED REGIMEN
Discontinuation of adherence to prescribed therapies remains an important obstacle to achieving treatment goals in patients with type 2 diabetes. Intolerability is the most common factor leading to medication discontinuation [e.g., hypoglycemia, gastrointestinal (GI) disturbances], although other factors such as natural history, complex daily regimens, out-of-pocket costs, and declining efficacy may also play a role. For example, a survey-based study of 2074 patients with type 2 diabetes found that over a 2-week period, 57% of participants reported symptoms of hypoglycemia, 28% reported constipation or diarrhea, and 21-26% experienced headaches, water retention, or weight gain. The important finding from this study in relation to adherence was that each additional tolerability issue was associated with a 28% increase in medication non-adherence [78] .
Hypoglycemia
Hypoglycemia is one of the more common tolerability/side effect issues leading to medication discontinuation. Incretin-based therapies induce the secretion of insulin from pancreatic tissue only in the presence of elevated blood glucose (e.g., 'glucosedependent insulin secretion'); these agents therefore pose a low risk for hypoglycemia. A recent claims database analysis specifically examined hypoglycemic events in more than 212,000 patients taking OADs from January 1999 through September 2008 [79] . The rates which is consistent with the results of another meta-analysis of linagliptin trials [85, 86] . A pooled analysis of data from sitagliptin trials (N = 10,246 patients with type 2 diabetes) showed that the rates of discontinuation due to AEs were similar in patients receiving sitagliptin versus comparators (4.4% versus 4.5%, respectively) [87] . These results are consistent with data from meta-analyses and systematic reviews showing an acceptable safety and tolerability profile for DPP-4 inhibitors [63, 84] .
Within the incretin-mimetics class, the most commonly occurring tolerability issue stems from GI side effects (e.g., nausea, abdominal discomfort, and vomiting) [88] . These may occur in up to 30% of patients, although the incidence of GI symptoms usually declines within the first month of therapy [89] [90] [91] . No studies have yet been published that describe adherence rates in patients taking the recently approved once-weekly formulation of exenatide. However, provided that the efficacy, AE profile, and rate of discontinuation of the once-weekly formulation is not significantly different from the older twice-daily formulation [92] , it may be expected that patient adherence to the onceweekly formulation may be improved as a result of its simpler dosing schedule.
Lastly, it has been shown that simplification of the dosing schedule can lead to significant improvements in medication adherence using fixed-dose combination (FDC) therapies. For example, a retrospective database review recently showed that patients with diabetes who were categorized by their physicians as adherent to their prescribed antihyperglycemic medication regimen were five times more likely to be taking an FDC than those who were described by physicians as non-adherent [93] . Initiation of treatment with an FDC is associated with greater adherence when compared with patients receiving the same medications as 'loose-pill combination.'
Authors of an analysis of seven studies that compared these strategies concluded that adherence was 13% greater in patients who started on FDCs [94] . Cheong et al. [95] demonstrated that when patients already 
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